Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Raafat E F Fahim"'
Publikováno v:
CNS & Neurological Disorders - Drug Targets. 10:905-915
Smoking is a global healthcare problem. Current smoking cessation rates using behavioral counseling and pharmacotherapeutic interventions have had modest success, with ∼1:5 smokers remaining abstinent long-term. Nicotine vaccines are a new class of
Autor:
Stephen I. Rennard, Nancy A. Rigotti, David Gonzales, Raafat E F Fahim, Matthew W Kalnik, Douglas E. Jorenby, Elbert D. Glover, Dorothy K. Hatsukami, Donald P. Tashkin, Cheryl Oncken, Minoo Niknian, Victor I. Reus, Paul D. Kessler, Roxanne C. Akhavain
Publikováno v:
Clinical pharmacology and therapeutics
Clinical pharmacology and therapeutics, vol 89, iss 3
Clinical pharmacology and therapeutics, vol 89, iss 3
NicVAX, a nicotine vaccine (3'AmNic-rEPA), has been clinically evaluated to determine whether higher antibody (Ab) concentrations are associated with higher smoking abstinence rates and whether dosages and frequency of administration are associated w
Autor:
Philippe Hoogsteder, Onno C. P. van Schayck, Daniel Kotz, Wolfgang Viechtbauer, Ruth Brauer, Paul I. van Spiegel, Raafat E F Fahim, Matthew W Kalnik, Paul D. Kessler
Publikováno v:
BMC Public Health, Vol 12, Iss 1, p 1052 (2012)
BMC Public Health
BMC Public Health, 12. BioMed Central Ltd
BMC Public Health
BMC Public Health, 12. BioMed Central Ltd
Background A potential new treatment in smoking cessation and relapse prevention is nicotine vaccination which is based on active immunization against the nicotine molecule. This immunization will elicit the immune system to produce nicotine-specific